2020
Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis
Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis. Leukemia 2020, 35: 1643-1660. PMID: 32868875, PMCID: PMC7917159, DOI: 10.1038/s41375-020-01020-4.Peer-Reviewed Original ResearchConceptsOverall response ratePEG-IFNPolycythemia veraEssential thrombocythemiaHematologic responsePV patientsResponse rateSystematic reviewMeta-regression analysis resultsSafe long-term treatmentPartial hematologic responseSafety of interferonInterferon-alpha therapyLong-term treatmentRandom-effects modelMeta-regression analysisWeb of ScienceTreatment discontinuationCochrane RegistryAdverse eventsComplete responsePartial responsePrimary outcomeThromboembolic complicationsClinical trialsLeukapheresis for the management of hyperleukocytosis in acute myeloid leukemia—A systematic review and meta‐analysis
Bewersdorf JP, Giri S, Tallman MS, Zeidan AM, Stahl M. Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia—A systematic review and meta‐analysis. Transfusion 2020, 60: 2360-2369. PMID: 32776542, PMCID: PMC8631180, DOI: 10.1111/trf.15994.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaEarly mortality rateWhite blood cellsRisk ratioMyeloid leukemiaMortality rateSystematic reviewShort-term mortality benefitHigh early mortality rateManagement of hyperleukocytosisCochrane Central RegisterIndividual study estimatesWeb of ScienceCentral RegisterMortality benefitControlled TrialsPrimary outcomeEarly mortalityRetrospective studyMultiarm studiesTreatment strategiesTwo-armEarly deathLeukapheresisPatientsInterferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis
Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Rampal RK, Tallman MS, Zeidan AM, Stahl M. Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis. Clinical Lymphoma Myeloma & Leukemia 2020, 20: e712-e723. PMID: 32669244, PMCID: PMC7541411, DOI: 10.1016/j.clml.2020.05.018.Peer-Reviewed Original ResearchConceptsOverall response rateTreatment of myelofibrosisPEG-IFNMF patientsResponse rateHematologic responseSystematic reviewFormulations of interferonPartial hematologic responseCochrane Central RegisterComplete hematologic responseRisk of progressionRole of interferonAcute myeloid leukemiaPhiladelphia chromosome-negative myeloproliferative neoplasmsRandom-effects modelBone marrow failureWeb of ScienceTreatment discontinuationCentral RegisterConstitutional symptomsHematologic improvementInterferon therapyAdverse eventsComplete response
2019
Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis
Stahl M, Bewersdorf J, Giri S, Wang R, Zeidan AM. Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis. Haematologica 2019, 105: 102-111. PMID: 31004015, PMCID: PMC6939518, DOI: 10.3324/haematol.2019.219345.Peer-Reviewed Original ResearchConceptsImmunosuppressive therapyProspective cohort studyMyelodysplastic syndromeClinical trialsResponse rateCohort studySystematic reviewLower-risk myelodysplastic syndromesLow-risk MDS patientsDifferent immunosuppressive regimensTransfusion independence rateAnti-thymocyte globulinComplete remission rateRelevant conference proceedingsOverall response rateTreatment of patientsAcute myeloid leukemiaHigh-quality studiesHigh response rateRandom-effects modelWeb of ScienceImmunosuppressive regimensPatient yearsRemission rateAdverse events